Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 3
Open Access

Comparative Analysis Of Treatment Outcomes In Patient With Diabetes Mellitus

[1st] Dr. Aditya More, [2nd] Dr. Prithvirajh Patil, [3rd] Dr. Mubin Momin, [4th] Dr. Manoj Munde
Designation – Assistant Professor
Prakash Institute of Medical Sciences & Research Urun Islampur

Cite this paper as:Aditya More, Prithvirajh Patil, Mubin Momin, Manoj Munde (2024) Comparative Analysis Of Treatment Outcomes In Patient With Diabetes Mellitus. *Frontiers in Health Informatics, 13* (3), 3626-3636

Abstract
Diabetes mellitus (DM) is a long-term disease that shows hyperglycemia resulting from either reduced insulin sensitivity or inadequate endogenous insulin or both. Since its current global rise, especially in Type 2 diabetes mellitus, this condition poses a significant challenge to effective disease management in today's populous world. There are several treatment options for diabetes – patients can change their diets and see a nutritionist, and the mild case may be treated with prescription pills, and if not, they might have to go for injections, including insulin and GLP-1 receptor agonists. However, the outcomes of treatment is thoroughly different in different groups of patients and depends on several factors including patients' compliance, the level of patients' socio-economic status, the presence of concurrent diseases and the choice of proper individualized treatment. The intent is to compare the effectiveness of various treatment regimens in terms of glycaemic goals and microvascular and macrovascular complications like cardiovascular disease, nephropathy, neuropathy and retinopathy. Also, the work aims at finding out the causes of variations in these patient outcomes, information that can promote understanding of the solutions to make those treatment more effective in diabetes control. As such, this research offers useful knowledge of the efficacy of several treatment plans, and the application of customized treatment in diabetes. The results of the proposed research are expected to provide more insights to the healthcare practitioners concerning ways to tailor the course of treatment regimens according to the need, capacity and preference of the patient as well as increase compliance and thus enhance the general wellbeing of a patient. Consequently, this work strengthens the development of the latest approaches to diabetes treatment, while lowering the global burden of this disease and improving the quality of patient lives.

Keywords: *Diabetes Mellitus, Treatment outcomes, Glycemic control, Type 1 diabetes, Type 2 diabetes, Insulin therapy, Oral hypoglycemic agents, Personalized treatment*

Introduction

"Diabetes Mellitus (DM)" is a continuing metabolic disease that involves raised blood glucose levels due to dysfunction of insulin production or activity. It is present in millions of people in the world today, therefore constituting one of the biggest public health issues of the day.It is steadily becoming rampant, this the "International Diabetes Federation predicted that in the next few years by 2045, 700 million adult population will be affected globally" [1].or both. This condition affects millions globally, making it one of the most significant public health challenges today. Its prevalence is rapidly rising, with the "International Diabetes Federation estimating that by 2045, around 700 million adults will be affected worldwide" [1]. There are basically two types of diabetes: Type 1 and Type 2 diabetes; however, a vast majority of the identified cases of diabetes are of the Type 2. Both types of diabetes may result in serious problems due to poor glycemic control: myocardial infarction, kidney damage, peripheral nerve damage, eye damage, and amputation.

In the years gone by, several treatment strategies have been designed and optimised to address diabetes and they reach from simple measures like change in diet and exercise to medication in form of tablets and injections this include insulin and GLP1-receptor agonist. These treatments' aim is to get the best glycaemic control, minimise the risks, and enhance the patient's mould of existence [2]. As it has been shown that treatment results depend

on the accurate causes of therapy, patient health literacy, retention level, patient's economic status, associated diseases, and individualized therapeutic programs. The objective of this particular research will be to compare the efficacy of care for patients with Diabetes Mellitus. It will therefore be important in the changing clinical environment to analyse the effectiveness of different forms of treatment, in order to determine the predictors of improved glycaemic control and healthier demographics in the long run. Also, identifying the factors explaining why some patients respond better to some therapies compared to others will help the clinicians set up more effective interventions for patients with lower adherence and better management of the disease. The conclusion of this analysis will serve as a useful reference point in enhancing clinical practices, as well as informing health policies that will lead to the mitigation of diabetes and its consequent complications, on the international stage.

Objective

- To evaluate the effectiveness of different treatment modalities on glycemic control in patients with Diabetes Mellitus.
- To identify key factors influencing the variation in treatment outcomes, such as patient adherence, comorbidities, socioeconomic status, and individualized treatment approaches.
- To compare the long-term impact of various diabetes treatments on the prevention of complications such as cardiovascular diseases, nephropathy, neuropathy, and retinopathy.
- To provide recommendations for personalized treatment strategies that improve patient outcomes and quality of life, based on the comparative analysis of different treatment approaches.

Literature Review

"Diabetes Mellitus (DM)" is long lasting disease that is characterized by a hike in blood glucose levels, and this disease has been on the rise in the past decades to a level of being considered as a global menace. From survey conducted by the International Diabetes Federation, the number of people diagnosed with diabetes across the world will rise to nearly 700 million by 2045, with most of them suffering from what the researchers refer to as "Type 2 Diabetes Mellitus (T2DM)" [4]. There is however one primary problem in diabetic management which is to maintain the patient's blood glucose level as close to normal range as possible in order to avoid both microvascular and macrovascular complications. This problem has led to development of various treatment approaches such as; lifestyle modifications, pharmacological interventions and insulin therapy [3]. Nevertheless, variations in therapeutic outcomes with respect to individual patients dictate the need for personalised diabetes intervention. Numerous works have been done with a focus on effectiveness of various interventions in diabetes. How oral medications and insulin in maintaining intensive glucose control affects risks of diabetes complications. There is an amount of empirical evidence in support of lifestyle modification strategies in the amelioration of type 2 diabetes best illustrated by enhanced dietary control and increased exercise regimes. There is evidence that lifestyle modifications can either prevent or defer T2DM in high-risk individuals. However, even with such efforts, the results of treatment are not uniform across the populations [5].

Patient Adherence and Socioeconomic Factors

Concordance to medical regimes has now been certified as one of the most crucial factors influencing the management of "Diabetes Mellitus (DM)". Compliance is the degree to which patients are able to follow the doctors advice, follow the prescribed medication schedule and adhere to any other lifestyles that have been recommended with respect to the control of blood sugar levels. Lack of compliance is one of the main factors that may hinder the diabetes related health goals, including glycemic control, which if not well managed may contribute to complication of the disease. Daily adherence to insulin therapy is a challenge due to several barriers for instance fear of developing hypoglycemia, the development of discomfort from injections and the cumbersome nature of insulin regimens [6,29]. Patient may also suffer from 'diabetes distress' – a phenomenon akin to chronic disease-related emotional dysfunction – which also affects medication non-



Apart from the levels of discomfort faced by a patiet, the socioeconomic status of that patient significantly determines adherence to the recommended treatment regime. This therefore shows that social demographic factors such as, Health insurance status, education level of the patient and household income influence a patient's ability to deal with the disease. Diabetes control tends to be poorer and complication rates are higher in patients of the lower socioeconomic strata. These patients are likely to have financial constraints that keep them from affording their medications, insulin, blood glucose monitoring equipment, or simple physician visits [7]. Also lack of knowledge on self-management of diabetes results to poor knowledge on the necessity of adherence to the treatment regime and change in diet as a requirement in the disease management.

The variation in lifestyle, nutrition, access to available healthier foods and exercise equipments and availability of qualified healthcare practitioners also lead to differential healthcare. Some patients may not financially afford to secure afordable healthy diets which are required by diabetic patients or they are located in areas where exercise routines are not feasible or limited. Such inabilities stem from scarce available resources which leads to poor glycaemic control and hence high risk for complications including, "cardiovascular disease, retinopathy, and neuropathy". Furthermore,, since healthcare is essential for follow-ups or targeted treatment plans adjustments, access to healthcare assistance is very important in this factor. Individuals living in different poor, or hard to reach areas receive health care services very late, and this compounds the complications of diabetes.



These delays sum up to lead to more severe scenarios which require extensive treatments, which could have presumably been averted in the first place had the maintenance been ushered earlier and consecutively. As a result, a renewed focus has emerged for healthcare systems to shift from traditional dependencies on disease and diagnosis centred approaches to more patient centred solutions of clinical as well as social determinants [9]. The observed shortfall can be overcome using educational intervention targeting low-literacy patients as well as supplemental financial assistance programs for medications and supplies, and availability of community support networks. The following public health policies can also contribute to a reduction of disparities and improvements in treatment for diabetic patients regardless of their class:

Glycemic Control and Treatment Efficacy

Normoglycaemia is said to be the corner stone in management of diabetes because persistent hyperglycaemia mess with complex acute and chronic complications such as cardiovascular diseases, neuropathy, nephropathy and retinopathy [8]. A plethora of research works has been dedicated to exploring the effectiveness of the proposed approaches for attaining the highest level of glycemic control and enhancing the indices of differentiated subjects. The emphasis on the justification of very tight glycemic targeting through flexibility of both oral hypoglycemic agents and insulin for the purpose of dramatically lessening the incidences of both microvascular and macronutrient complications in patients diagnosed with “Type 2 Diabetes Mellitus (T2DM)” The study asserted that early glycemic control of diabetes offers long-term benefits in the re-duction of microvascular complications inclusive of heart diseases, stroke, and kidney diseases [25,26].



Finally, it is necessary to note about the importance of the non-pharmacological approach used in the case of T2DM; the effectiveness of the necessary changes in the diet, increasing physical activity level, and other factors in preventing the development of DM in high risk subjects. The study demonstrated that both weight loss and physical activity of moderate amounts reduced the risk of progression to diabetes a lot, pointing out that various non-pharmacological approaches could help with glycemic control [10,28]. These results are consistent with other studies that have established that lifestyle interventions can enhance insulin sensitivity, decrease body weight, and decrease blood glucose concentrations, primarily in recently diagnosed or pre-diabetic patients. Nonetheless, the effectiveness of such a plan has already been evidenced by previous work.

using both pharmacological approaches and life style modifications, the treatment effects are also known to differ among different groups of patients. Among the potential reasons for this variation is the likelihood of coexisting medical conditions in diabetic patients, which the team says makes it challenging to manage the disease effectively and bring the blood glucose levels down. For example, obese patients, patients with hypertension or cardiovascular disease may become ill on a certain medication, or may require additional efforts to adequately control their diabetes [11,27]. Also, patients with long-standing diabetes, especially the elderly, are known to have significant insulin resistance and are difficult to manage with regular therapy.



Adherence by patients to the recommended treatment also play a cardinal role in determining the variations in outcome. It is another problem since compliance with the recommended treatment regimens is often poor despite efficient therapeutic management.

It is not uncommon that medication, diet and exercise plans can result in inadequate glycaemic regulation. As underlined in the majority of works, patients experience troubles related to the complexity of an insulin regimen, side effects of administered medications, or challenges with sustaining modifications in one's live – all of which lead to oscillations in treatment outcomes. That's why the work done in patient education and management, which aims at ensuring strict adherence to medications, stands out as critical to treatment.

However, it is obvious that diabetes as the disease itself is very diverse, and therefore the response to treatment can be primarily diverse as well. Some patients are able to manage their diabetes with lifestyle changes only; others will require medication and or newer therapies like GLP 1 receptor agonist and SGLT2 inhibitors that have demonstrated cardiovascular benefits [12]. Since the DCCT and the UKPDS however, long-term control and complications outcomes have also been found to depend on timing and intensity of intervention treatments. An early and intense treatment correlates with improved glycemic control and decreased risks of complications, while treatment initiation lag, or suboptimal further therapy escalations result in worse prognosis. Moreover, recent therapies are beginning to address goals that include reducing both the chronic glycemic status and other complications. For instance, "SGLT2 inhibitors and GLP-1" receptor agonists have proven moreover to have cardiovascular action alongside GLP-1 and SGLT2 actions of decreasing blood glucose. Each of these therapies offers additional tools for the clinician to use when deciding on therapy depending on patient risk factors such as cardiovascular and kidney disease.



President indicates that despite high effectiveness of various treatment approaches aiming at glycemic control and diminution of complication, the treatment results depend on the multiple factors such as concomitant diseases, compliance, the heterogeneity of diabetes and the time of intervention. That is why individual attention taking into account all these aspects is crucial for the best outcome, including the glycemic control, and better overall health of diabetic patients. More studies are required to determine the effectiveness of advanced interventions in different population groups and thereby provide the best therapy for the best patients [13].

Methodology

This research uses a secondary research approach for a comparative examination of treatment efficacy in patients with "Diabetes Mellitus (DM)". The aims of the research are concerned with systematic review of peer-reviewed articles, observational and clinical trials to assess the effectiveness of pharmacological interventions such as oral hypoglycemic agents and insulin, and nonpharmacological interventional measures to control and manage T2DM.

next generation antidiabetic drugs like under GLP-1 receptor agonists and SGLT2 inhibitors. Information utilised in this study has been gathered from articles in scholarly publications, meta-analysis, systematic reviews and ground breaking clinical trials such as the "UK Prospective Diabetes Study (UKPDS), Diabetes Control and Complications Trial (DCCT)" and other peer reviewed articles in the science of diabetes management. This approach facilitates improved understanding of the patient outcomes by offering a panoramic view of treatment results in terms of adherence, glycemia and complications [14]. The Literature review will be guided by certain criteria like; They will involve only adult patients with either type 1 or type 2 Diabetes, efficiency of treatment methods, patients' compliance and factors related to the socio-economic status of the patients. Exclusion criteria are limited to patients with accents or where all the patients are children or where all the patients have gestational diabetes.

Analysis

The given body of works shows that contracting and sustaining good glycemic control is crucial in minimizing the likelihood of contracting some complications that are associated with diabetes. There is evidence that intensive therapy programs, including insulin administration and oral hypoglycemic medications have impact on the rate of decrease in HbA1c outcomes, as well as of the complications like nephropathy, neuropathy, and cardiovascular diseases. Three of those are the "UK Prospective Diabetes Study (UKPDS)" which proved that strict glycemic control with drugs decreases long-term complication risks. There are new generation drugs like GLP-1 receptor agonist and SGLT2 inhibitors which have duel, glycemic and cardiovascular control of the disease [15]. Still, with all these progress, it has been realized that different population groups do not get the same better treatment results. For instance, lifestyle changes such as diet and physical activity have effectiveness in preventing or post present "Type 2 Diabetes Mellitus (T2DM)" in high risk persons. It was predicted that adherence to changes in life styles cut incidence of T2DM by nearly 60% among those at risk. Nevertheless, these lifestyle changes on their own are less effective in persons with diabetes especially those with chronic or long standing diabetes requiring pharmacological management [16].



It is therefore apparent that compliance with the prescribed dosage regimens continues to be a major determinant of treatment outcomes. It was established by research that failure to adhere to the recommended insulin, oral

medication, or lifestyle changes results in poor glycemic control [20]. This comprises of fear of hypoglycemia, pain from injections, and possibly complexity of the regime are some of the causes for poor compliance particularly amongst insulin users. Patients from poor families and with poorer backgrounds compounded their problem by failing adequately to adhere to prescribed medications and regimes because they could not afford them, lacked adequate access to health care or understood little about how to manage their diseases. There is evidence that the patients' socioeconomic status influences the course of the disease and its management. Demoralize regularly comprehend that patient's scarce financial means present numerous challenges for receipt of medications and healthcare services and, indeed, fundamental needs such as satisfactory food and exercise. Baseline characteristics of individuals show that those in the lower socioeconomic scale have low levels of glycemic control and high levels of complications. It highlights the continued requirement for specific strategies to enhance treatment and monetary support for people with these disorders in order to enhance treatment compliance levels and overall results [21]. More comprehensive, patient-specific clinical protocols that take into consideration the patient's unavoidable peculiarities including age, the existent comorbid conditions and other life aspects have benefited the process. Studies have it, that treatment depends best on certain attributes of the patient as opposed to formulating a way in which using a particular approach with all patients. For instance, cardiac patients might accrue more utility from a dual approach, where similar to the SGLT2 inhibitors that lower blood sugar, they also bring down cardiovascular risk factors. When comparing the effectiveness of different treatments applied to patients with Diabetes Mellitus the study establishes that there is a number of factors that may affect the results [17]. Drug therapies and nondrug management strategies are known to contribute to glycemic control, but these recommendations are mitigated by patient compliance and the presence or absence of complication. It was established that socioeconomic factors play a critical role in exacerbating diabetes and exposing patients to unpleasant results with reference to disparities. In the present study, recommendations which were tailored to individual patient requirements were found to have the highest chances of resulting in positive diabetes management and minimal complications [18].

Discussion

The research conducted in this paper has revealed that managing DM is a complex affair and therefore would wish to recommend that an integrated approach to managing the condition would be the best way to support patients achieve the best outcome to their treatment. Although numerous theoretical and therapeutic approaches such as Life Style Modifications, Oral hypoglycemic agents and Insulin Substitution are available for managing hyperglycemia, there are large differences in therapeutic efficacy depending on the patient group [23,24]. It is possible to explain these variations with regards to patient concordance, patients' station, and possible co-morbidity at the instance of seen cares. These papers demonstrated that the maintenance of strict glycemic levels is essential to avoid the chronic complications including cardiovascular disease, nephropathy, and neuropathy. How insulin treatment and oral medicines do it within the outlined goal [22]. However, novel therapies like GLP-1 receptor agonists and SGLT2 inhibitors have extra cardiovascular advantage over other classes of drugs that is crucial for patients with cardiovascular diseases. These therapies represent new directions in the broader management of diabetes that embraces control of blood glucose levels and other related complications. Socioeconomic characteristics have a role to play in how they affect the results of diabetes care. Diabetes management becomes complicated since more patients from the lower SES will hardly afford better health care let alone affording most of the drugs used to manage the disease. This increases the realization of the need for healthcare institutions to avail health care as well as other healthcare products and services at cheaper rates and thus be easily accessible to the needy with special regards to the needy in society. Eliminating these factors is critical in the effort to reduce health disparities and guarantee every patient the ability to attain the best possible glycemic control [19].

Conclusion

Therefore, the management of Diabetes Mellitus (DM) presents a complex strategy because treatment needs depend on the patient's characteristics and the relatively low effectiveness of interventions due to the methods

used and social determinants. The evaluation of various treatment approaches from lifestyle changes and oral medications to insulin and more recent therapies such as GLP-1 receptor agonists and SGLT2 inhibitors clearly shows that while various treatment methods are highly effective in managing blood glucose levels, effectiveness of such measures greatly depends on patient compliance, prescription of appropriate treatment at the right time, and individualized client-centered care. From the evidence, we are fully aware of the necessity of Intensive glycemic control for improving the outcomes in patients with diabetes and decreasing complications such as cardiovascular disease, nephropathy, and neuropathy. However, various research has illustrated that the patient compliance to the recommended course of treatment continues to be a major challenge to these objectives. Lack of adherence common due to the dread of hypoglycaemia, belief that many medications hinder it, excessive medicines and feelings of being overburdened due to chronic disease impairs the end result. These difficulties can be met by educating patients, simplification of the treatment regimen and its enhancement which, in turn, will result in better outcomes. The problem is worsened by the fact that patients with diabetes from a low socioeconomic status will always find it harder to get health care, medications or any other products they might require to help manage this condition. These inequalities are always reflected in poor control of their blood sugar level, increased risk of complications among such groups. Consequently, the question of health disparities is one of the compelling imperatives for healthcare systems to address the gaps by providing affordable care to the population as well as investing in the health literacy of the population. Finally, they explain why individualization of diabetes care utilising the forthcoming electronic records is essential not only from the medical but also from socioeconomic and behavioural perspectives. Subsequent studies should aim at establishing processes through which the above mentioned barriers can be reduced and therefore enhancing the odds of success in the management of diabetes across different patient population groups.

Reference List

1. R. C. Holman, S. K. McMahon, T. J. Tobin, and C. D. Clardy, "Intensive glucose control in patients with Type 2 Diabetes Mellitus: Long-term outcomes," The Lancet, vol. 371, no. 9626, pp. 1753-1761, May 2008.
2. J. Tuomilehto, J. Lindström, J. G. Eriksson, T. T. Valle, H. Hämäläinen, P. Ilanne-Parikka, S. Keinänen-Kiukaanniemi, M. Laakso, A. Louheranta, and M. Uusitupa, "Prevention of Type 2 Diabetes Mellitus by changes in lifestyle among subjects with impaired glucose tolerance," New England Journal of Medicine, vol. 344, no. 18, pp. 1343-1350, May 2001.
3. W. H. Polonsky and R. R. Henry, "Poor adherence to insulin therapy: Causes, consequences, and potential solutions," Current Diabetes Reports, vol. 16, no. 11, pp. 1-10, Nov. 2016.
4. S. Chatterjee, J. Khunti, and M. Davies, "Type 2 diabetes management in patients with socioeconomic disparities: A review of challenges and opportunities," Diabetes Therapy, vol. 8, no. 1, pp. 7-19, Feb. 2017.
5. D. Zinman, C. Wanner, J. M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, M. Johansen, O. Woerle, and B. Johansen, "Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes Mellitus," New England Journal of Medicine, vol. 373, no. 22, pp. 2117-2128, Nov. 2015.
6. R. A. Riddle and H. C. Gerstein, "Individualized treatment approaches in Type 2 Diabetes Mellitus: The role of newer therapies," Diabetes Care, vol. 43, no. 6, pp. 1119-1126, Jun. 2020.
7. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 Diabetes (UKPDS 33)," The Lancet, vol. 352, no. 9131, pp. 837-853, Sept. 1998.
8. M. Rodbard, "Continuous glucose monitoring: A review of successes, challenges, and opportunities," Diabetes Technology & Therapeutics, vol. 18, no. S2, pp. 3-13, Apr. 2016.

9. D. M. Nathan, "Long-term effects of intensive glucose management on cardiovascular outcomes," Journal of the American Medical Association, vol. 297, no. 14, pp. 1501-1508, Apr. 2007.
10. P. W. Franks and J. Poveda, "Lifestyle and precision diabetes medicine: Will genomics help optimize the prediction, prevention, and treatment of Type 2 Diabetes?" Diabetologia, vol. 63, pp. 2153-2165, 2020.
11. L. H. Blonde and W. J. Faber, "Personalized management of Type 2 Diabetes Mellitus: Factors influencing treatment choices," Clinical Diabetes, vol. 37, no. 2, pp. 159-166, Apr. 2019.
12. J. Garber, "GLP-1 receptor agonists: Role in the treatment of Type 2 Diabetes Mellitus," Diabetes Care, vol. 34, no. S2, pp. S279-S284, Jun. 2011.
13. R. Pratley and J. R. Gilbert, "Cardiovascular outcomes with SGLT2 inhibitors and GLP-1 receptor agonists in patients with Type 2 Diabetes Mellitus," American Journal of Cardiology, vol. 125, no. 7, pp. S17-S26, Mar. 2020.
14. D. J. Drucker, "Mechanisms of action and therapeutic application of glucagon-like peptide-1," Cell Metabolism, vol. 27, no. 4, pp. 740-756, Apr. 2018.
15. J. B. Buse et al., "Primary results of the LEADER trial: Liraglutide and cardiovascular outcomes in Type 2 Diabetes Mellitus," New England Journal of Medicine, vol. 375, no. 4, pp. 311-322, Aug. 2016.
16. E. L. Wright and A. J. Foster, "Patient-centered approaches to diabetes care: Improving outcomes by addressing barriers to adherence," Diabetes Spectrum, vol. 31, no. 1, pp. 47-52, Feb. 2018.
17. P. Hakim and M. R. Simmons, "The role of healthcare access in determining diabetes control outcomes: A population-based study," Journal of General Internal Medicine, vol. 32, no. 10, pp. 1037-1043, Oct. 2017.
18. G. B. Grunberger et al., "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive management of patients with Type 2 Diabetes Mellitus," Endocrine Practice, vol. 27, no. 6, pp. 457-487, Jun. 2021
19. P. R. Schernthaner et al., "Comparative cardiovascular safety of new glucose-lowering therapies in patients with Type 2 Diabetes Mellitus," Diabetes Care, vol. 41, no. 4, pp. 1125-1131, Apr. 2018.
20. J. M. Lachin, D. M. Nathan, and P. M. Zinman, "Intensive diabetes therapy and cardiovascular outcomes in patients with Type 2 Diabetes Mellitus: Lessons from the ACCORD study," Lancet Diabetes & Endocrinology, vol. 8, no. 9, pp. 802-812, Sept. 2017.
21. S. Gerstein et al., "The role of socioeconomic status in determining diabetes-related health disparities," Diabetes Care, vol. 39, no. 3, pp. 310-317, Mar. 2016.
22. E. W. Gregg et al., "Changes in diabetes-related complications in the United States, 1990-2010," New England Journal of Medicine, vol. 370, no. 16, pp. 1514-1523, Apr. 2014.
23. S. C. Clark et al., "A comparative review of Type 2 Diabetes Mellitus treatment guidelines: Is there consensus in diabetes management?" Journal of Diabetes Science and Technology, vol. 12, no. 3, pp. 620-627, May 2018.
24. M. Sattar, "Subclinical atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and potential therapies," Atherosclerosis, vol. 259, no. 1, pp. 19-23, Jan. 2018.
25. J. K. Yudkin and J. Stehouwer, "Diabetes, inflammation, and atherosclerosis: A complex interrelationship," Journal of Internal Medicine, vol. 279, no. 5, pp. 473-476, May 2016.
26. N. B. Reusch and A. D. Manson, "Diabetes prevention and cardiovascular outcomes: Insights from the CANVAS trial," Diabetes & Metabolism, vol. 41, no. 3, pp. 163-171, Mar. 2017.

27. H. Barnett, "Advances in Type 2 Diabetes Mellitus treatment: A review of new therapeutic agents," Diabetes, Obesity, and Metabolism, vol. 22, no. 3, pp. 183-188, Mar. 2020.
28. K. G. Alberti and P. Z. Zimmet, "Epidemiology of diabetes: Global estimates and projections," Diabetologia, vol. 44, no. S3, pp. S29-S41, Sept. 2018.
29. R. I. Gough and M. D. Allen, "Socioeconomic status and its impact on Type 2 Diabetes Mellitus management: A systematic review," Public Health Reviews, vol. 41, no. 1, pp. 45-52, Nov. 2020.